All articles tagged with #zolgensma
A five-year-old boy from Colchester with SMA has made remarkable progress after receiving the world's most expensive gene therapy, Zolgensma, which has transformed his mobility and quality of life, highlighting significant advances in treatment for rare genetic conditions.
Patients with spinal muscular atrophy (SMA) who received the gene therapy Zolgensma are increasingly requiring additional drugs, raising questions about the long-term effectiveness and value of high-cost gene therapies. While Zolgensma has shown positive results for many patients, a significant number have needed supplementary treatments to achieve desired outcomes. This challenges the perception that gene therapies can provide a complete cure and raises concerns about the justification of their exorbitant prices. The experience with Zolgensma highlights the need for further research and real-world data to determine the true value and cost-effectiveness of gene therapies.